Objective:s To investigate the risk factors for delayed encephalopathy after acute carbon monoxide poisoning (DEACMP) in patients with acute carbon monoxide poisoning (ACOP) and to develop predictive models based on machine learning algorithms.Methods:Patients with ACOP hospitalized at the First Affiliated Hospital of Zhengzhou University from August 2019 to October 2024 were included, with the occurrence of DEACMP as the outcome measure. The dataset was randomly divided into training and validation sets at a ratio of 7:3. Lasso regression was used to select features influencing the outcome in training sets. Nine machine learning models—including Random Forest (RF), Extreme Gradient Boosting (XGBoost), and Support Vector Machine (SVM)—were constructed. Receiver operating characteristic (ROC) curves were plotted and the area under the curve (AUC) calculated for each model. Calibration curves were used to assess accuracy, and decision curve analysis (DCA) was applied to evaluate clinical utility. The SHapley Additive exPlanations (SHAP) method was employed to visualize and interpret the best-performing model.Results:A total of 264 ACOP patients were included, of whom 54 (20.5%) developed DEACMP. Lasso regression identified eight key feature variables. Based on these factors, predictive models were constructed, showing good AUC stability across the nine machine learning models in both training (0.92–0.99) and validation sets (0.85–0.91). The RF model performed best, with an AUC of 0.99 in the training set and 0.90 in the validation set; its calibration curve and DCA curve also demonstrated excellent performance. SHAP analysis of the RF model revealed the importance ranking of factors from highest to lowest as follows: Glasgow Coma Scale (GCS) score, duration of coma, age, history of coronary heart disease, CK-MB level, monocyte count, diastolic blood pressure (DBP), and drinking history.Conclusions:The RF model exhibited the highest predictive performance for DEACMP occurrence in ACOP patients. The influencing factors, ranked in order of importance from highest to lowest, are as follows: GCS score, duration of coma, age, history of coronary heart disease, CK-MB level, monocyte count, DBP, and drinking history.

Ivonescimab is a humanized bispecific antibody targeting human vascular endothelial growth factor-A(VEGF-A)and programmed death protein-1(PD-1).It was approved by National Medi-cal Products Administration on May 24th,2024,and can be used in combination with pemetrexed and carboplatin for locally advanced or positive EG-FR gene mutation after treatment with epidermal growth factor receptor(EGFR)tyrosine kinase inhib-itor.This paper mainly introduces the research progress of the world's first PD-1/VEGF bispecific antibody ivonescimab,and summarizes the mecha-nism of action,pharmacokinetics,phase Ⅰ-Ⅲ clinical trials and drug safety.

Objective:To investigate the efficacy of toric intraocular lens (IOL) combined with capsular tension rings (CTR) in the treatment of high myopia complicated by corneal astigmatism and cataract and its effects on visual acuity.Methods:A retrospective study was conducted on 80 eyes of 80 patients with high myopia complicated by corneal astigmatism and cataract who received treatment at Baoji People's Hospital from December 2021 to December 2023. Based on the treatment methods, the patients were divided into two groups. The study group was treated with toric IOL combined with CTR, while the control group was treated with toric IOL only. The best corrected visual acuity, corneal astigmatism, visual quality, the degree of intraocular lens rotation, and the incidence of postoperative complications were compared between the two groups before and after surgery.Results:After surgery, the best corrected visual acuity and corneal astigmatism in the study group were significantly better than those in the control group [(0.18 ± 0.24) LogMAR vs. (0.23 ± 0.16) LogMAR, t = 4.05, P < 0.001; (0.73 ± 0.22) D vs. (0.45 ± 0.26) D, t = 6.79, P = 0.001]. At 1 month post-surgery, the visual quality scores in the study group were significantly higher than those in the control group ( t = 5.36, 6.35, 7.14, 4.25, all P < 0.05). At 1 week, 1 month, 3 months, and 6 months after surgery, the degrees of intraocular lens rotation in the study group were less than those in the control group ( t = 5.59, 2.70, 4.22, 6.10, all P < 0.05). At 6 months post-surgery, the incidence of complications in the study group was lower than that in the control group [20.00% (8/40) vs. 45.00% (18/40), χ2 = 5.70, P = 0.017]. Conclusions:Toric IOL combined with CTR treatment can effectively improve the visual function in patients with high myopia complicated by corneal astigmatism and cataract. This approach reduces the incidence of postoperative complications and minimizes astigmatism, proving to be both safe and effective.

Lumbar disc herniation(LDH)is a common and frequent disease,also one of the main causes of low back and lower limb pain.Radiomics can be used to improve early diagnosis of LDH,assist individualized treatment plan and evaluate prognosis.The research progresses of radiomics for early diagnosis and treatment of LDH were reviewed in this article.

Lumbar disc herniation(LDH)is a common and frequent disease,also one of the main causes of low back and lower limb pain.Radiomics can be used to improve early diagnosis of LDH,assist individualized treatment plan and evaluate prognosis.The research progresses of radiomics for early diagnosis and treatment of LDH were reviewed in this article.

Ivonescimab is a humanized bispecific antibody targeting human vascular endothelial growth factor-A(VEGF-A)and programmed death protein-1(PD-1).It was approved by National Medi-cal Products Administration on May 24th,2024,and can be used in combination with pemetrexed and carboplatin for locally advanced or positive EG-FR gene mutation after treatment with epidermal growth factor receptor(EGFR)tyrosine kinase inhib-itor.This paper mainly introduces the research progress of the world's first PD-1/VEGF bispecific antibody ivonescimab,and summarizes the mecha-nism of action,pharmacokinetics,phase Ⅰ-Ⅲ clinical trials and drug safety.

Objective:To investigate the efficacy of toric intraocular lens (IOL) combined with capsular tension rings (CTR) in the treatment of high myopia complicated by corneal astigmatism and cataract and its effects on visual acuity.Methods:A retrospective study was conducted on 80 eyes of 80 patients with high myopia complicated by corneal astigmatism and cataract who received treatment at Baoji People's Hospital from December 2021 to December 2023. Based on the treatment methods, the patients were divided into two groups. The study group was treated with toric IOL combined with CTR, while the control group was treated with toric IOL only. The best corrected visual acuity, corneal astigmatism, visual quality, the degree of intraocular lens rotation, and the incidence of postoperative complications were compared between the two groups before and after surgery.Results:After surgery, the best corrected visual acuity and corneal astigmatism in the study group were significantly better than those in the control group [(0.18 ± 0.24) LogMAR vs. (0.23 ± 0.16) LogMAR, t = 4.05, P < 0.001; (0.73 ± 0.22) D vs. (0.45 ± 0.26) D, t = 6.79, P = 0.001]. At 1 month post-surgery, the visual quality scores in the study group were significantly higher than those in the control group ( t = 5.36, 6.35, 7.14, 4.25, all P < 0.05). At 1 week, 1 month, 3 months, and 6 months after surgery, the degrees of intraocular lens rotation in the study group were less than those in the control group ( t = 5.59, 2.70, 4.22, 6.10, all P < 0.05). At 6 months post-surgery, the incidence of complications in the study group was lower than that in the control group [20.00% (8/40) vs. 45.00% (18/40), χ2 = 5.70, P = 0.017]. Conclusions:Toric IOL combined with CTR treatment can effectively improve the visual function in patients with high myopia complicated by corneal astigmatism and cataract. This approach reduces the incidence of postoperative complications and minimizes astigmatism, proving to be both safe and effective.

Objective To observe the protective effect of Zhilong Huoxue Tongyu Capsule(Zhilong Capsule)on myocardial ischemia reperfusion injury(MIRI)in mice,and explore its regulatory mechanism using metabolomics.Methods Using a random number table method,30 C57BL/6J mice were randomly divided into the following three groups:sham operation group,model group,and Zhilong Capsule group(6.24 g/kg),with 10 mice in each group.In mice in the model group and the Zhilong Capsule group,a mouse MIRI model was established by ligating the left anterior descending branch,while mice in the sham operation group underwent threading without ligation.The Zhilong Capsule group began modeling one week after pre-administration and continued to receive intragastric administration for two weeks after modeling once daily.The cardiac function,including the left ventricular ejection fraction(LVEF)and left ventricular fraction shortening(LVFS),was assessed by color echocardiography.The myocardial fibrosis and apoptosis were observed by Masson staining and TUNEL staining,respectively.Enzyme-linked immunosorbent assay was used to measure the serum contents of lactate dehydrogenase(LDH)and brain natriuretic peptide(BNP).Liquid chromatography-mass spectrometry combined with multivariate statistical method was performed for serum metabolite detection and identification analysis.Results Compared with the model group,the mice in the Zhilong Capsule group exhibited an increase in LVEF and LVFS,a reduction in cardiac tissue structure disorder,a decrease in myocardial fibrosis,a decrease in cell apoptosis rate,and a decrease in serum LDH and BNP contents(P<0.05).Metabolomics result showed that intervention with Zhilong Capsule significantly regulated 30 differential metabolites related to MIRI.Important metabolic pathways involved 20 pathways related to tyrosine metabolism,arginine and proline metabolism,and vitamin digestion and absorption.Conclusion Zhilong Capsule has a protective effect on MIRI,and it may achieve this effect by regulating pathways related to tyrosine metabolism,arginine and proline metabolism,and vitamin digestion and absorption.

Metabolic regulation has been proven to play a critical role in T cell antitumor immunity. However, cholesterol metabolism as a key component of this regulation remains largely unexplored. Herein, we found that the low-density lipoprotein receptor (LDLR), which has been previously identified as a transporter for cholesterol, plays a pivotal role in regulating CD8